Member News

£100,000 February

Additional funding January

This algae-to-neutraceuticals company has attracted increasing interest since Beer first raised startup capital for it in Q2 2009. It is now approaching seven-figure revenues, is cashflow-positive, is enjoying vigorous growth in demand for its initial product 'Astaxanthin', and is likely to be capacity-constrained for the foreseeable future. As the business has become 'derisked', it attracts more widespread attention, and that figure may rise.

£600,000 April

This diversified manufacturer of small scale renewable energy products came to Beer & Partners in mid- January 2012, seeking to complete its latest £1.3m round of fundraising having £700,000 already committed from existing and new investors. Investments from two Beer Investors were secured with one agreeing terms within three weeks of meeting and a second within one week. In fact this round could have been oversubscribed by almost a quarter.

Additional £86,000 March

A group of Beer Investors have invested alongside both existing and other new investors into this spin out from St Andrews University. The company has developed and launched a range of products that allow treatment of commonly occurring skin cancers to be carried in the primary care arena rather than within specialist dermatology clinics. This funding round will take the business into profitability and allow the company to roll out its technology into other common skin treatment areas.